Opsoclonus-myoclonus syndrome during rituximab treatment for autoimmune autonomic ganglionopathy

Oana M. Dumitrascu; Andrew McKeon; Leslie Zuniga; Marie F. Grill; Brent P. Goodman

doi:10.1212/NXI.0000000000000376

Opsoclonus-myoclonus syndrome during rituximab treatment for autoimmune autonomic ganglionopathy

Oana M. Dumitrascu, Andrew McKeon, Leslie Zuniga, Marie F. Grill, Brent P. Goodman

Laboratory Medicine and Pathology

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Original language	English (US)
Article number	376
Journal	Neurology: Neuroimmunology and NeuroInflammation
Volume	4
Issue number	5
DOIs	https://doi.org/10.1212/NXI.0000000000000376
State	Published - 2017

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1212/NXI.0000000000000376

Cite this

@article{fa5999878ebd4dc0a5ea7880f6d529e4,

title = "Opsoclonus-myoclonus syndrome during rituximab treatment for autoimmune autonomic ganglionopathy",

author = "Dumitrascu, {Oana M.} and Andrew McKeon and Leslie Zuniga and Grill, {Marie F.} and Goodman, {Brent P.}",

note = "Funding Information: Disclosure: O.M. Dumitrascu reports no disclosures. A. McKeon has patents pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; consulted for Grifols, MedImmune, and Euroimmun; and received research support from MedImmune. L. Zuniga and M.F. Gill report no disclosures. B.P. Goodman consulted for Lundbeck. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the Mayo Clinic. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.",

year = "2017",

doi = "10.1212/NXI.0000000000000376",

language = "English (US)",

volume = "4",

journal = "Neurology: Neuroimmunology and NeuroInflammation",

issn = "2332-7812",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

TY - JOUR

T1 - Opsoclonus-myoclonus syndrome during rituximab treatment for autoimmune autonomic ganglionopathy

AU - Dumitrascu, Oana M.

AU - McKeon, Andrew

AU - Zuniga, Leslie

AU - Grill, Marie F.

AU - Goodman, Brent P.

N1 - Funding Information: Disclosure: O.M. Dumitrascu reports no disclosures. A. McKeon has patents pending for GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders; consulted for Grifols, MedImmune, and Euroimmun; and received research support from MedImmune. L. Zuniga and M.F. Gill report no disclosures. B.P. Goodman consulted for Lundbeck. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the Mayo Clinic. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PY - 2017

Y1 - 2017

UR - http://www.scopus.com/inward/record.url?scp=85029075370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029075370&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000376

DO - 10.1212/NXI.0000000000000376

M3 - Short survey

AN - SCOPUS:85029075370

SN - 2332-7812

VL - 4

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

IS - 5

M1 - 376

ER -

Opsoclonus-myoclonus syndrome during rituximab treatment for autoimmune autonomic ganglionopathy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this